Particle.news

Australia Gets Wegovy Tablet as Regulators Tighten GLP‑1 Safety Rules

Daily oral GLP-1s increase access, raise urgent questions about safety, cost, long-term care

Overview

  • Australia’s Therapeutic Goods Administration cleared the Wegovy tablet and Foundayo, and the Wegovy pill began appearing on pharmacy shelves on Sunday, giving patients a daily oral option alongside existing injections.
  • Regulators in the US, UK and Australia have recently tightened oversight by updating safety labels for rare vision and pancreatitis risks and by imposing stricter online prescribing checks.
  • Clinicians report real-world harms when GLP-1s are used without multidisciplinary support, including cases of malnutrition and severe muscle loss such as a patient who lost 10 kilograms of muscle mass.
  • Trials and clinical data show stopping GLP-1 treatment typically causes rapid weight regain and reversal of metabolic gains, so doctors urge planning for long-term management with diet, exercise and monitoring.
  • Use and sales have surged in recent years—research finds almost a tenfold rise in Australia—and governments are negotiating limited subsidies while many new combination drugs remain in late-stage trials.